Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- Bacterial Infection
- Drug Discovery
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 336318
Licensor Patents shall mean
U.S. Patent # 6,830,753 – Adsorbent for oral administration
U.S. Patent # 5,686,081 – Divided package of adsorbent for internal use
U.S. Patent # 5,554,370 – Method for the treatment of inflammatory bowel diseases
This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas. AST-120 is an oral agent known to adsorb bile acids, toxins and mediators of inflammation from the gastrointestinal tract with the potential to address multiple gastrointestinal diseases.
Licensee also recently announced the initiation of Phase 2 trials with AST-120 in Irritable Bowel Syndrome and Hepatic Encephalopathy.
Irritable bowel syndrome (IBS), referred to previously as spastic or nervous colon, and spastic bowel, is a functional gastrointestinal disorder characterized by a group of symptoms accompanied together that include abdominal pain and changes in the consistency of bowel movements. Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that you'll need to manage long term.
Hepatic encephalopathy (HE) is a common neuropsychiatric complication of liver disease.
IPSCIO Record ID: 266736
Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.
Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.
IPSCIO Record ID: 233469
Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.
Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.
First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years. Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.
IPSCIO Record ID: 314635
Compound means YH12852, which has the chemical structure set forth in this agreement, together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.
Licensor Patent Rights means all Patent Rights in the Territory that are Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term (other than Joint Patent Rights) that Cover any Compound or Product. The Licensor Patent Rights existing as of the Effective Date are set forth on Schedule 1.57; provided, however, that, if Licensor is acquired by a Third Party, â€œLicensor Patent Rightsâ€ shall exclude any Patent Rights that (a) are Controlled by such Third Party or the Affiliates of such Third Party (other than Licensor and Licensor Pre-Existing Affiliates) and (b) were not Controlled by Licensor or any of the Licensor Pre-Existing Affiliates immediately prior to the closing of such acquisition transaction; provided further that, if, after the closing of such acquisition, any such Licensor Excluded Affiliate has or acquires Control of any Patent Right that Covers the Development, Manufacture or Commercialization of any Compound or Product and that is used to Develop, Manufacture or Commercialize any such Compound or Product, such additional Patent Right that is Controlled by such Licensor Excluded Affiliate shall be included in Licensor Patent Rights.
9,890,138 – Diaminopyrimidine derivatives and processes for the preparation thereof
10,227,330 – Diaminopyrimidine derivatives and processes for the preparation thereof
9,850,227 – Diaminopyrimidine derivatives and processes for the preparation thereof
Licensee is a global pharmaceutical company offering one-stop custom synthesis services of active pharmaceutical products (APIs) and intermediates.
YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis.
IPSCIO Record ID: 2810
Compound means 2-di-n-propylamino-8-(isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and solvates.
Gastrointestinal Indications means disease states, such as excess gastric acid secretion, inflammatory bowel disease, irritable bowel syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis, hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation and diarrhea, which are characterized by abnormalities of the Digestive System, regardless of the mechanism involved in such disease states.
IPSCIO Record ID: 263902
The name of the product is SalofalkÂ® 500 mg, Granu-StixÂ®. Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.
The patents include Pellet formulation for the treatment of the intestinal tract, and, Pellet-type formulation intended for treating the intestinal tract.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.
IPSCIO Record ID: 264191
ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.
IPSCIO Record ID: 367311
Licensor hereby grants to Licensee a co-exclusive right and license, with the right to grant sublicenses solely as set forth in this agreement, under the Licensor Intellectual Property and Licensorâ€™s rights in the Joint Intellectual Property to the extent necessary or useful to Manufacture the Compound and Product in the Field in the Territory for Development and Commercialization by Licensee in the Territory.
USAN – TEDUGLUTIDE
Therapeutic Claim – treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease (glucagon-like peptide-2 (GLP-2) analog)
Licensor Patent Rights shall mean Patent Rights, to the extent that they (a) Cover Licensor Know-How or are directly related to the Manufacture, use, Commercialization or Development of Compound or Product in the Field, and (b) are Controlled by Licensor, but shall not include Joint Patent Rights.
GATTEX is an analog of glucagon-like peptide 2, a naturally occurring hormone that regulates proliferation of the cells lining the small intestine. Licensor is independently investigating GATTEX as a potential treatment for short bowel syndrome, or SBS, and other indications, including Crohnâ€™s disease, chemotherapy-induced enteritis, necrotizing enterocolitis and various other gastrointestinal diseases.
IPSCIO Record ID: 367296
(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertain to the manufacture of products within the United States;
(b) All applicable rules of the Funding Agencies which have provided funding to Licensor or to any of its employees (including any of the Inventors) for the development of the Patent Rights and Technical Information; and
(c) The following non-exclusive rights to the Patent Rights and Technical Information, which are retained by Licensor within the Field of Use
(i) the right to submit for publication the scientific findings from research conducted by or through Licensor or its investigators (including the Inventors) related to the Patent Rights and the Technical Information; and
(ii) the right (A) to use any tangible or intangible information contained in the Patent Rights or the Technical Information or any Improvements (so long as Licensor shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for Licensorâ€™s internal non-commercial scientific, research, internal teaching, non-profit clinical research and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).
(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights, Technical Information and Improvements outside of the Field of Use are retained by Licensor. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of Licensor other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.
6,861,053 – Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
6,805,852 – Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
7,056,686 – Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth
Archaea is a group of primitive prokaryotes that based on their distinct characteristics form a separate domain from bacteria and eukaryotes. Bacteria are single-celled primitive organisms that form a domain of organisms diverse in shape, size, structure, and even habitats.
IPSCIO Record ID: 253982
Licensor grants to Licensee, a perpetual, non-exclusive license under the Licensor Technology for Licensees research purposes only.
GI Indication means diseases, disorders or impairments of the gastrointestinal tract, including the esophagus, stomach, pancreas, small and large intestines, colon, and gall bladder.
GI Product means a Licensed Product that has been Approved in a GI Indication.
The compound is 9O-(N-methylamidomethyl)-Ndesmethyl-N-isopropyl-(9S)-9-dihydroerythromycin A.
The patents are for Motilide Compounds, Method for Evaluating Therapeutic Efficacy, ll-Deoxy-6,9-ether Erythromycin Compounds, N-Desmethyl-N-substituted-11-deoxyerythromycin Compounds, and, 9-Desoxoerythromycin Compounds as Prokinetic Agents.
Motilin, a hormone that is secreted by the small intestine, stimulates gastrointestinal motility (movement). Erythromycin, a polyketide best known for its antibiotic activity, is an agonist of the motilin receptor that enhances esophageal motility in GERD patients and accelerates gastric emptying in patients with diabetic gastroparesis.
Licensee believes that the mechanism of action of KOS-2187 and its demonstrated activity as a prokinetic agent are significant indications of its potential as a new approach for the treatment of gastrointestinal diseases.
IPSCIO Record ID: 57817
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tractâ€”the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.
Gastroenteritis and gastritis – 24 mg strength
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) â€“ 24 mg strength
IPSCIO Record ID: 266852
Licensor grants the exclusive right to use and to disclose to Third Parties all regulatory and clinical documentation and data developed by or on behalf of Licensor in the Territory in connection with this Agreement and required to be disclosed to Licensee under this Agreement, as reasonably necessary or desirable in connection with the development and commercialization of pharmaceutical products in the Field in the Rest of World or outside the Field throughout the world.
Licensor agrees to negotiate in good faith with Licensee concerning the terms of a license under the Licensor Patents and the Licensor Know-How covering the composition of matter or the use of the Terminated Compounds, to permit Licensee to research, develop, make, have made, import, use, sell and offer for sale the Terminated Compounds outside the Field throughout the world.
Licensor grants an exclusive, including with regard to Licensor, right and license in the Rest of World under the Licensor Patents and the Licensor Know-How and under Licensors rights in the Joint Patents, Joint KnowHow and Joint Research Technology, to research and develop, and to make, have made, import, use, sell and offer for sale pharmaceutical products, including Licensed Products, in the Field.
Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound. Development Compound means any Collaboration Compound that has
been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.
The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.
Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.
Licensee possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.